Topic: mergers and acquisitions
Analytica Laser has a novel system which the company touts as the industry's first dynamic tool to predict real-world health outcomes.
Will Johnson & Johnson be looking to beef up its pipeline with its R&D boost?
Investment firm Altaris Capital Partners is acquiring Analogic, the maker of ultrasound systems, in a deal worth $84 per share, or about $1.1 billion.
The takeover furthers Alexion’s pipeline rebuild by giving it control of WTX101, a phase 3 treatment for the rare genetic disorder Wilson disease.
The buyout gives Promethera control of a TNF receptor 1 inhibitor it hopes will amplify the effects of cell therapy HepaStem.
Newly minted CEO Vas Narasimhan is paying a hefty premium to establish Novartis as a frontrunner in the emerging gene therapy sector.
The medtech giant is paying $40 million upfront to add Securus’ FDA-cleared temperature monitoring system to its portfolio of cardiac rhythm products.
Genae's CEO says the transaction reflects recent focus on digital health and data-driven services.
The sale narrows GE’s focus to the diagnostic imaging and mobile monitoring businesses that generate most of its medtech sales.
The takeover will add a minimally invasive way of destroying obstructive prostate tissue to Boston Scientific’s urology business.